A user discussed the "Rootique Duo," a device that turns minoxidil into mist for scalp application, but others suggested cheaper alternatives like an AliExpress applicator. Some users prefer traditional methods like droppers or spray nozzles, especially for longer hair.
A 27-year-old Asian male is treating hair loss with 1mg oral finasteride, topical minoxidil twice daily, and 1.5mm microneedling weekly. The discussion is about his progress with these treatments.
The conversation discusses the sale of a premixed KY19382 solution for research purposes, highlighting previous unsuccessful group buys and the formulation process. Prices and purchasing options for KY19382 solutions and powder are provided.
The conversation is about the effectiveness of using less than 20mg of RU58841, specifically 12.5mg, for hair loss treatment. People are discussing their experiences with different dosages of RU58841.
The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.
Avixis Alfatradiol is a topical 5-alpha reductase inhibitor available in Latin America and Germany, but its effectiveness is questioned. A user reported worsened hair loss after using it and recommended finasteride instead due to its proven effectiveness and lower cost.
Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.
The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.
The user experienced side effects from finasteride and is considering adding Alfatradiol or Fluridil to their regimen, which includes Minoxidil, dermarolling, and ketoconazole. Fluridil is noted to be more effective than Alfatradiol but less effective than finasteride, with mild side effects reported.
A user is considering switching from oral to topical finasteride to reduce systemic DHT impact and is exploring ethossomal finasteride for better skin penetration and potential hair regrowth. They found ethossomal finasteride in Brazil and are seeking opinions on its effectiveness compared to other topical delivery methods.
The conversation is about using a Dr. Pen for microneedling on a widow's peak, with advice to use a depth of 1.25mm and hold it in place for 10 seconds. The user is also using minoxidil.
The conversation is about the effectiveness of the Laduora duo massage brush for hair regrowth using vibration and red light, and whether the vitamin gel pods make sense. Specific treatments like Minoxidil, finasteride, and RU58841 are not mentioned.
The conversation is about a topical spray containing finasteride, minoxidil, and tretinoin, with users discussing its effectiveness compared to more established brands. One user mentions using a product with 5% minoxidil, 0.15% finasteride, and 0.15% tretinoin.
The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.
Tretinoin and microneedling both enhance hair growth through different mechanisms, with microneedling being considered safe for long-term use. Optimal microneedling needle length varies, but 0.8 mm is suggested for hair growth, and a Dermastamp is recommended to avoid skin damage.
OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.
The user is experiencing scalp irritation from using RU58841 with a 70% ethanol and 30% propylene glycol vehicle and is considering switching to a less irritating vehicle, such as 30% ethanol with 70% squalane or emu oil. They are seeking feedback on the effectiveness and irritation levels of these alternative carriers.
The user has been taking oral Finasteride and topical Essengen 6 Plus for hair loss and is experiencing increased depression. They plan to get bloodwork to check hormone levels and are seeking advice on which tests to include.
The conversation discusses using Actifolic tretinoin to enhance the absorption of Minoxidil for hair loss treatment. It questions the amount of tretinoin to use and whether to apply it before or after Minoxidil.
The user is asking about the safety of using RU58841 when trying to conceive and if others have had healthy babies after using it. They are seeking advice on how long to take a break from RU58841 before attempting to have a baby.
Topical dutasteride 0.05% is reported to outperform oral finasteride with minimal side effects, but concerns about study bias exist due to company funding. Some users report mixed results with topical dutasteride, noting issues with skin penetration and systemic absorption.
Vitamin D may counteract DHT and help with hair growth, as seen in mice and human hair cultures. Some users discuss using Vitamin D, magnesium, and other supplements for hair health, while others humorously note the success in mice.
A 31-year-old has been on finasteride for 8 years and is experiencing less dense hair and itchiness, and is considering adding minoxidil or RU58841 to their regimen. They are also inquiring about the benefits of oral versus topical finasteride.
The user is experiencing diffuse thinning and their dermatologist recommended starting with oral minoxidil due to its safer profile. They are seeking opinions on whether to start with minoxidil or consider finasteride, and are concerned about potential side effects.
Fluridil's effectiveness and safety in treating hair loss are discussed, with higher concentrations showing potential success. Comparisons are made to other treatments like RU58841, Pyri, CB-03-01, and topical spironalactone.
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.